Literature DB >> 34468985

Seizures' impact on cognition and quality of life in childhood cancer survivors.

Nicholas S Phillips1, Raja B Khan2, Chenghong Li3, Sedigheh Mirzaei Salehabadi3, Tara M Brinkman1,4, Deokumar Srivastava3, Leslie L Robison1, Melissa M Hudson1,5, Kevin R Krull1,4, Zsila S Sadighi2.   

Abstract

BACKGROUND: The objective of this study was to determine the impact of seizure-related factors on neurocognitive, health-related quality of life (HRQOL), and social outcomes in survivors of childhood cancer.
METHODS: Survivors of childhood cancer treated at St. Jude Children's Hospital (n = 2022; 48.3% female; median age, 31.5 years; median time since diagnosis, 23.6 years) completed neurocognitive testing and questionnaires. The presence, severity, resolution, and treatment history of seizures were abstracted from medical records. Adjusting for the age at diagnosis, sex, and prior cancer therapy, multivariable models examined the impact of seizures on neurocognitive and HRQOL outcomes. Mediation analyses were conducted for social outcomes.
RESULTS: Seizures were identified in 232 survivors (11.5%; 29.9% of survivors with central nervous system [CNS] tumors and 9.0% of those without CNS tumors). In CNS tumor survivors, seizures were associated with poorer executive function and processing speed (P < .02); in non-CNS tumor survivors, seizures were associated with worse function in every domain (P < .05). Among non-CNS survivors, seizure severity was associated with worse processing speed (P = .023), and resolution was associated with better executive function (P = .028) and attention (P = .044). In CNS survivors, seizure resolution was associated with improved attention (P = .047) and memory (P < .02). Mediation analysis revealed that the impact of seizures on social outcomes was mediated by neurocognitive function.
CONCLUSIONS: Seizures in cancer survivors adversely affect long-term functional and psychosocial outcomes independently of cancer therapy. The resolution of seizure occurrence is associated with better outcomes. Seizure severity is associated with poorer outcomes and should be a focus of clinical management and patient education.
© 2021 American Cancer Society.

Entities:  

Keywords:  brain tumor; cancer survivors; leukemia; neurocognitive; seizure

Mesh:

Year:  2021        PMID: 34468985      PMCID: PMC8678188          DOI: 10.1002/cncr.33879

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  44 in total

1.  A national profile of childhood epilepsy and seizure disorder.

Authors:  Shirley A Russ; Kandyce Larson; Neal Halfon
Journal:  Pediatrics       Date:  2012-01-23       Impact factor: 7.124

2.  Survivors of childhood cancer in the United States: prevalence and burden of morbidity.

Authors:  Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04       Impact factor: 4.254

3.  Topiramate dose effects on cognition: a randomized double-blind study.

Authors:  D W Loring; D J Williamson; K J Meador; F Wiegand; J Hulihan
Journal:  Neurology       Date:  2010-12-09       Impact factor: 9.910

4.  Mesial temporal spikes interfere with working memory.

Authors:  G L Krauss; M Summerfield; J Brandt; S Breiter; D Ruchkin
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

Review 5.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

6.  Early seizure onset and dysplastic lesion extent independently disrupt cognitive networks.

Authors:  Brandon Korman; Pavel Krsek; Michael Duchowny; Bruno Maton; Esperanza Pacheco-Jacome; Gustavo Rey
Journal:  Neurology       Date:  2013-07-19       Impact factor: 9.910

7.  Differential cognitive and behavioral effects of topiramate and valproate.

Authors:  K J Meador; D W Loring; J F Hulihan; M Kamin; R Karim
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

8.  Long-Term Neurocognitive Functioning and Social Attainment in Adult Survivors of Pediatric CNS Tumors: Results From the St Jude Lifetime Cohort Study.

Authors:  Tara M Brinkman; Matthew J Krasin; Wei Liu; Gregory T Armstrong; Rohit P Ojha; Zsila S Sadighi; Pankaj Gupta; Cara Kimberg; Deokumar Srivastava; Thomas E Merchant; Amar Gajjar; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

9.  The impact of limitations in physical, executive, and emotional function on health-related quality of life among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Kirsten K Ness; James G Gurney; Lonnie K Zeltzer; Wendy Leisenring; Daniel A Mulrooney; Paul C Nathan; Leslie L Robison; Ann C Mertens
Journal:  Arch Phys Med Rehabil       Date:  2008-01       Impact factor: 4.060

10.  Physical fitness and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime cohort.

Authors:  Nicholas S Phillips; Carrie R Howell; Jennifer Q Lanctot; Robyn E Partin; Ching-Hon Pui; Melissa M Hudson; Leslie L Robison; Kevin R Krull; Kirsten K Ness
Journal:  Cancer       Date:  2019-10-21       Impact factor: 6.921

View more
  1 in total

1.  Patient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma.

Authors:  Nina S Kadan-Lottick; Daniel J Zheng; Mingjuan Wang; Michael W Bishop; Deo Kumar Srivastava; Wilhelmenia L Ross; Rozalyn L Rodwin; Kirsten K Ness; Todd M Gibson; Sheri L Spunt; Mehmet Fatih Okcu; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  J Cancer Surviv       Date:  2022-01-21       Impact factor: 4.062

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.